Lumida
/CRDF
⌘K
Cardiff Oncology Inc

Cardiff Oncology Inc

CRDF
$1.21USD+0.00%+0.00 today

MARKET CAP

94.1M

P/E (TTM)

FWD P/E

DAY RANGE

$1 – $1

52W RANGE

$1
$3

AI Summary

Stalk
TrimMedium

CRDF remains in Stage 4 decline with medium-term bearish bias—execution should focus on trimming into rallies around the declining 9/21 EMA zone and prior consolidation highs. Short-term timing is neutral amid extreme oversold conditions, suggesting deferred engagement until relief bounces stall.

  • Onvansertib shows 64% ORR in 30 mg cohort vs 33% in control arm.
  • Strategic shift to first-line RAS-mutated mCRC backed by FDA guidance.
  • Q4 cash burn of ~$10.3M per quarter strains the $91.7M runway.
Full analysis →
Insider Trades3 trades
DateSideTickerInsiderRoleSharesPriceMkt Cap52W High52W LowValue% ChgRuleAI View
Jul 14, 2026BuyCRDFMani MohindruChief Executive Officer34,364$1.46$94.1M-63.44%+59.93%$50.0K+58.18%Trim
Jun 18, 2026BuyCRDFMani MohindruChief Executive Officer24,703$1.21$94.1M-63.44%+59.93%$29.9KTrim
Dec 16, 2024BuyCRDFJames E. LevineChief Financial Officer7,716$4.76$94.1M-63.44%+59.93%$36.7K+4.11%Trim